Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) Income from Continuing Operations (2016 - 2025)

Iradimed (IRMD) has disclosed Income from Continuing Operations for 13 consecutive years, with 5576652.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 10.44% to 5576652.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 20487168.0, a 9.99% increase, with the full-year FY2024 number at 18536374.0, up 7.81% from a year prior.
  • Income from Continuing Operations was 5576652.0 for Q3 2025 at Iradimed, down from 5773961.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5773961.0 in Q2 2025 to a low of 1386849.0 in Q1 2021.
  • A 5-year average of 3893976.84 and a median of 4136533.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 279.2% in 2021; the steepest drop was 21.61% in 2021.
  • Iradimed's Income from Continuing Operations stood at 3892667.0 in 2021, then fell by 3.97% to 3738027.0 in 2022, then grew by 21.45% to 4539686.0 in 2023, then decreased by 1.99% to 4449126.0 in 2024, then grew by 25.34% to 5576652.0 in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Income from Continuing Operations are 5576652.0 (Q3 2025), 5773961.0 (Q2 2025), and 4687429.0 (Q1 2025).